仑卡奈单抗注射液 | China Drugs ListLecanemab injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- Eisai Inc.
- 药品类型
- 生物药Biologic
- 治疗领域
- 神经科Neurology
- 公开来源记录的适应症
- 本品用于治疗由阿尔茨海默病引起的轻度认知障碍和阿尔茨海默病轻度痴呆。Treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia.
- 适应症来源与口径
- 来源日期： 2025, 2026. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- 说明书信息局限
- 已取得完整官方药品说明书。 现有完整说明书来自海外辖区；尚未取得完整的中国现行说明书。中国适应症另由中国来源支持。Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 日本, 英国: 已取得当地获批／上市公告及官方价格来源。每条价格记录注明适应症与日期；未全面核查其他市场。Japan, United Kingdom: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
- 医保分类
- 未纳入基本医保；已入2025商保创新药目录Commercial insurance list only; not included in basic insurance
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 商保目录不由基本医保基金支付；具体商业保险以合同为准Inclusion in the commercial insurance drug list does not imply payment by the basic medical insurance fund. Commercial insurance coverage depends on the individual policy.
- 医保核查说明
- 商业保险目录精确匹配；基本医保通知排除支付。Exact match in the commercial insurance list; the basic insurance notice excludes payment.